The use of the drug combined with an innovative vaping cessation counseling program was safe and effective for quitting e-cigarettes. The combined approach also decreased the chances of relapsing back to vaping and smoking.
During the 2023 edition of the GFN, a pool of international diabetologists, coordinated by CoEHAR, addressed the issue of cigarette smoking among diabetes patients, setting new international treatment guidelines to be published soon.
In May, CoEHAR has launched one of its most ambitious project, the Veritas Cohort study. Now, more than 400 people from 27 different countries are involved and numbers keep increasing.
GFN 2023 will start tomorrow at Varsavia. The 10th edition of the Global Forum on Nicotine, from 21 to 24 June, will host more events dedicated to harm reduction research. During this edition will be also the second meeting of SAB Diasmoke. Diabetologists and experts on THR signed the guidelines on the treatment of smokers with diabetes.
Currently visiting professor at the University of Catania, prof. Roberto Sussman accepted to hold a Lectio Magistralis at the biological tower: he explained the real life usage of electronic cigarettes and the physics behind the environmental emission of ecig
Aim of the trip was to conduct and perform further technical training of the partners on biological endpoints and dissemination of Tobacco Harm Reduction mission and research.
“It is a fact that in Italy there are millions of smokers who are unwilling or unable to quit smoking – explained prof. Riccardo Polosa, founder of CoEHAR - These smokers do not accept to be medicalized because of their smoking habit and in Italy, even today, we do not have a health policy that takes care of these people. Risk reduction is the solution. In countries with a liberal approach, such as Sweden or England, which have chosen to open up to alternative nicotine release tools by promoting them in the cessation paths for heavy smokers, the prestigious smoke-free goal is being reached. It is time to follow these virtuous examples also in Italy".
Dr. Rosalia Emma will discuss the presentation “Inhalation preclinical assessment: In vitro science for real life user” during the panel dedicated to “Tackling concerns around industry standards”.
"From biologic mechanisms to theragnostic paths in the Hereditary Cancer Syndromes: germline mutations as a therapeutic target" is the title of the meeting held at the Temple University, Friday, May 12. Although hereditary cancer…
According to Prof. Polosa: “The study does not present any causality between data and the hypothesis according to which there would be health complications for vapers”, In fact, as the scientist explains: “The very small sample size and low reproducibility of the tests does not allow us to give a precise and scientific answer on pulmonary inflammation caused by vaping because it does not take into consideration fundamental factors, such as the prior exposure to tobacco smoking”.
We will send you direct emails, without intermediary services, you can withdraw any time.
Copyright 2021 – Center of Excellence for the acceleration of Harm Reduction. All rights reserved.